Skip to main content
. 2009 May 4;29(13):3582–3596. doi: 10.1128/MCB.01417-08

FIG. 4.

FIG. 4.

Effects of mutation of LKB1 Ser307 to alanine on AMPK and LKB1 activity.(A) LKB1-deficient A549 cells were transfected with WT LKB1 and LKB1 mutants. After the transfection, the cells were pretreated with PKC-ζ-PS (10 μM, 30 min) followed by treatment with ONOO− (50 μM, 15 min). AMPK was immunoprecipitated with AMPKα1/2 antibody, and AMPK activity was detected as described in Materials and Methods. n = 6. ♣, P < 0.01 for WT LKB1 treated with ONOO− versus untreated WT LKB1 and LKB1 mutants treated with ONOO−; †, P < 0.01 for ONOO−-treated WT LKB1 in the presence of PKC-ζ-PS compared with ONOO−-treated WT LKB1 in the absence of PKC-ζ-PS. con, control. (B) A549 cells were transfected with WT LKB1 and LKB1 mutants and treated with ONOO− (50 μM, 15 min). LKB1 was immunoprecipitated with specific antibody, and its activity was measured as described in Materials and Methods. n = 4. (C) LKB1 was immunoprecipitated from A549 cells transfected with WT LKB1 and LKB1 mutants, the immunoprecipitates were incubated with 100 ng of recombinant PKC-ζ, and LKB1 activity was assayed using LKB1-specific peptide. n = 3.